Want to see AU:ADR full AI Analyst Report?
ADR Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$0.19
Previous CloseN/A
Volume40.01K
Average Volume (3M)1.17M
Market Cap
AU$7.14M
Enterprise ValueAU$4.54M
Total Cash (Recent Filing)AU$642.27K
Total Debt (Recent Filing)AU$1.33M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding54,887,287
10 Day Avg. Volume107,278
30 Day Avg. Volume1,170,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.76
Price to Sales (P/S)4.40
P/FCF Ratio-0.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)99.26
Revenue Forecast (FY)AU$54.78M
Bulls Say, Bears Say
Bulls Say
Recurring Software/data RevenueThe company earns recurring fees from software and data services tied to its inhaler sensors. Recurring revenue models increase predictability and customer lifetime value, supporting margin improvement and more stable cash flows over a multi-month horizon.
Partnerships With Pharma And HealthcareCollaborations and contracts with pharma, healthcare providers, and research programs create multi-year commercial and trial opportunities. Such partnerships can provide steady program revenues, validation for the technology, and routes to scale beyond direct device sales.
Focused Product-market Fit In Respiratory CareAdherium’s sensor-plus-platform focus on inhaler adherence for asthma and COPD addresses a persistent clinical need. The combination of hardware and analytics is sticky for patients, providers and pharma, creating durable demand driven by chronic disease management.
Bears Say
Negative Shareholders' EquityNegative equity signals solvency stress and constrains financial flexibility. It raises refinancing and covenant risk, can limit access to debt or favorable terms, and increases the likelihood of dilutive equity raises or restructuring to sustain operations over coming months.
Weak Cash GenerationDeteriorating free cash flow and operating cash flow that does not cover losses indicate the business requires external funding to operate. Persistent negative cash generation undermines the ability to invest in commercialization or R&D without dilutive financing.
Declining Revenue And Negative MarginsFalling revenue paired with sustained negative EBIT and net margins points to shrinking market traction or pricing pressure and operational inefficiency. Continued losses reduce reinvestment capacity and lengthen the timeline to reach sustainable profitability.
Adherium Ltd. News
ADR FAQ
What was Adherium Ltd.’s price range in the past 12 months?
Adherium Ltd. lowest share price was AU$0.13 and its highest was AU$0.19 in the past 12 months.
What is Adherium Ltd.’s market cap?
Adherium Ltd.’s market cap is AU$7.14M.
When is Adherium Ltd.’s upcoming earnings report date?
Adherium Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 58 days.
How were Adherium Ltd.’s earnings last quarter?
Adherium Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.294 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.294.
Is Adherium Ltd. overvalued?
According to Wall Street analysts Adherium Ltd.’s price is currently Overvalued.
Does Adherium Ltd. pay dividends?
Adherium Ltd. does not currently pay dividends.
What is Adherium Ltd.’s EPS estimate?
Adherium Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adherium Ltd. have?
Adherium Ltd. has 54,887,287 shares outstanding.
What happened to Adherium Ltd.’s price movement after its last earnings report?
Adherium Ltd. reported an EPS of -AU$0.294 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of Adherium Ltd.?
Currently, no hedge funds are holding shares in AU:ADR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adherium Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ADR Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$345.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Fundamentals
Return on Equity
459.94%
Trailing 12-Months
Asset Growth
-14.68%
Trailing 12-Months
Company Description
Adherium Ltd.
Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spanning New Zealand, Australia, Europe, North America, and Asia. A central offering is Hailie, a comprehensive system engineered to optimize medication use for patients suffering from chronic respiratory illnesses like asthma and chronic obstructive pulmonary disease (COPD). This innovative solution integrates Bluetooth-enabled Hailie sensors, which discreetly attach to patients' inhalers to deliver immediate feedback. The Hailie ecosystem is further supported by an intuitive mobile application and a dedicated online portal. Established in 2001, Adherium Limited is headquartered in Auckland, New Zealand.
Options Prices
Currently, No data available
---